Table 2 Summary ORs and 95% CI of microRNA polymorphisms and HNC risk.

From: Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis

Locus	N^*	No. of case/control	OR	95% CI	P	I²(%)^a	OR	95% CI	P	I²(%)^a	OR	95% CI	P	I²(%)^a	OR	95% CI	P	I²(%)^a	OR	95% CI	P	I²(%)^a
rs2910164 G > C			C vs. G				GC vs. GG				CC vs. GG				GC + CC vs.GG				CC vs. GG + GC
Total	7	3841/7900	1.20	1.04–1.39	0.01	77.9	1.27	1.05–1.55	0.02	68.4	1.27	0.86–1.88	0.22	80.8	1.30	1.07–1.58	0.01	70.0	1.12	0.83 –1.53	0.46	82.4
Ethnicity
Caucasian	3	2185/2499	1.15	0.98–1.33	0.08	56.0	1.31	1.01–1.68	0.04	75.3	0.96	0.50–1.83	0.89	75.0	1.26	1.02–1.57	0.03	68.7	0.87	0.42–1.79	0.71	80.2
Asian	4	1656/5401	1.24	0.96–1.61	0.10	86.3	1.25	0.86–1.82	0.23	71.5	1.54	0.93–2.55	0.10	83.6	1.37	0.92–2.04	0.13	78.2	1.30	0.92–1.83	0.14	84.1
Design
Population	3	2066/2330	1.23	0.93–1.62	0.15	88.2	1.24	0.85–1.83	0.27	81.3	1.15	0.79–2.88	0.21	88.9	1.33	0.86–2.06	0.19	87.1	1.27	0.89–1.83	0.19	75.8
Hospital	2	938/893	1.13	0.78–1.65	0.52	84.0	1.35	1.07–1.70	0.01	0.0	1.29	0.76–2.53	0.45	54.6	1.33	1.06–1.68	0.02	4.1	1.11	0.54–2.28	0.78	66.4
Healthy	2	837/4677	1.25	1.02–1.53	0.03	57.3	1.24	0.85–1.83	0.19	63.2	0.92	0.29–2.95	0.89	90.2	1.37	1.14–1.66	0.01	0	0.84	0.22–3.24	0.81	94.6
Location
HN	3	2047/2023	1.09	0.89–1.32	0.41	69.8	1.16	1.00–1.33	0.04	34.3	1.08	0.83–1.39	0.57	18.8	1.18	0.95–1.46	0.13	48.7	0.95	0.76–1.15	0.52	36.5
Thyroid	2	1361/1661	1.09	0.98–1.22	0.12	0	1.22	0.76–1.97	0.41	86.4	0.77	0.36–1.62	0.48	81.6	1.20	0.87–1.64	0.27	72.6	0.71	0.27–1.86	0.48	93.0
Genotyping
AB	3	1041/5117	1.40	1.08–1.81	0.01	79.2	1.53	1.06–2.20	0.02	66.0	1.43	0.51–4.03	0.50	91.9	1.63	1.12–2.39	0.01	71.2	1.15	0.54–2.42	0.72	91.0
PCR–RFLP	2	1579/1555	1.00	0.89–1.12	0.98	0	1.08	0.92–1.27	0.35	0	1.00	0.76–1.32	0.98	0	1.06	0.91–1.24	0.47	0	0.89	0.72–1.10	0.30	0
rs11614913 C > T			T vs. C				CT vs. CC				TT vs. CC				CT + TT vs. CC				TT vs. CC + CT
Total	5	3534/3564	1.10	1.03–1.19	0.01	0	1.25	0.98–1.59	0.08	72.5	1.21	1.04–1.41	0.01	2.5	1.16	0.95–1.44	0.15	69.1	1.09	0.96–1.23	0.19	40.7
Ethnicity
Asian	3	1593/1685	1.14	1.04–1.25	0.01	0	1.32	0.90–1.94	0.12	81.2	1.33	1.09–1.61	<0.01	0	1.32	0.99–1.76	0.06	69.7	1.14	0.99–1.33	0.08	44.8
Design
Population	3	2613/2691	1.08	0.99–1.18	0.08	0	1.07	0.93–1.24	0.35	0	1.14	0.96–1.36	0.14	0	1.03	0.88–1.19	0.74	34.3	1.11	0.84–1.43	0.40	66.5
Hospital	2	921/873	1.16	1.01–1.33	0.03	0	1.57	0.95–2.57	0.08	77.7	1.47	1.08–2.00	0.02	0	1.50	1.02–2.20	0.04	66.6	0.99	0.78–1.26	0.91	19.8
Location
HN	3	2063/2110	1.07	0.97–1.18	0.21	0	1.49	0.83–2.26	0.18	86.7	1.24	0.84–1.83	0.28	63.3	1.18	0.82–1.69	0.38	83.4	0.95	0.80–1.13	0.54	0
Genotyping
AB	3	1955/2009	1.14	1.03–1.27	0.01	0	1.08	0.90–1.28	0.40	35.3	1.27	1.02–1.58	0.04	0	1.05	0.85–1.29	0.67	55.3	1.25	1.05–1.49	0.01	0
PCR–RFLP	2	1579/1555	1.07	0.97–1.18	0.21	0	1.49	0.83–2.26	0.18	86.7	1.17	0.95–1.44	0.15	63.3	1.40	0.85–2.32	0.18	84.1	0.95	0.80–1.13	0.54	0
rs2292832 C > T			T vs. C				CT vs. CC				TT vs. CC				CT + TT vs. CC				TT vs. CC + CT
Total	3	1852/1677	1.04	0.85–1.28	0.71	60.4	1.18	0.67–2.06	0.57	75.8	1.15	0.63–2.12	0.65	77.8	1.18	0.68–2.05	0.55	78.8	0.98	0.81–1.19	0.86	0
Ethnicity
Asian	2	743/547	1.12	0.74–1.69	0.60	76.6	1.37	0.40–4.71	0.62	86.6	1.40	0.42–4.71	0.59	87.1	1.39	0.41–4.69	0.59	88.2	1.05	0.82–1.34	0.73	0
Genotyping
AB	2	743/547	1.12	0.74–1.69	0.60	76.6	1.37	0.40–4.71	0.62	86.6	1.40	0.42–4.71	0.59	87.1	1.39	0.41–4.69	0.59	88.2	1.05	0.82–1.34	0.73	0
Design
Hospital	2	743/547	1.12	0.74–1.69	0.60	76.6	1.37	0.40–4.71	0.62	86.6	1.40	0.42–4.71	0.59	87.1	1.39	0.41–4.69	0.59	88.2	1.05	0.82–1.34	0.73	0
rs3746444 A > G			G vs. A				AG vs. AA				GG vs. AA				AG + GG vs. AA				GG vs. AA + AG
Total	2	1579/1555	1.29	0.59–2.80	0.52	95.4	1.22	0.53–2.82	0.64	94.8	1.77	0.43–7.33	0.43	78.6	1.27	0.54–3.01	0.59	95.4	1.68	0.50–5.64	0.40	71.5

Population: Population controls Hospital: Hospital controls Healthy: Healthy controls.
HN: head and neck.
ABI: Applied Biosystems.
^*Numbers of comparisons.
^aTest for heterogeneity.

Back to article page

Table 2 Summary ORs and 95% CI of microRNA polymorphisms and HNC risk.

Search

Quick links